Melbek

Quick links to important sections

Melbek

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Melbek

Quick Facts

Property Description
Active ingredient Meloxicam
Forms Tablet, Capsule, Oral Suspension, Intravenous Solution
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Mechanism Type Preferential COX-2 Inhibitor
Origin Synthetic Compound

Melbek: Definition and Pharmacological Classification

Melbek is a trade name for a medicine containing the active ingredient Meloxicam. This substance is a synthetic compound chemically classified as an oxicam derivative and belongs to the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a group clinically recognized for their properties in managing pain and inflammation.

The defining characteristic of Meloxicam is its function as a preferential Cyclooxygenase-2 (COX-2) inhibitor. This selective mechanism is intended to better target the COX-2 enzyme, which escalates the production of prostaglandins—the chemical signals that cause swelling and pain during inflammation. Unlike older, less selective NSAIDs, Meloxicam's profile as a preferential inhibitor is a key differentiator in its therapeutic application.

Composition, Form, and General Purpose

Meloxicam is a single active ingredient product, meaning it contains only one therapeutic compound designed to exert anti-inflammatory and analgesic effects. It is manufactured in various pharmaceutical preparations, including common oral forms like the tablet and oral suspension, facilitating administration across different patient groups. The overall purpose of Melbek is to provide sustained relief from the physical manifestations of inflammatory conditions. For instance, the drug is typically used to ease the persistent stiffness and pain associated with chronic joint conditions, helping to reduce swelling and relieve localized discomfort.

What side effects are possible with Melbek?

Possible Side Effects and Safety Information

The official safety information for this medicine, as documented by government regulatory bodies, emphasizes two primary Serious Warnings concerning critical, potentially fatal adverse events.


Serious Adverse Reactions

  • Cardiovascular Thrombotic Events: Use of this medicine is associated with an increased risk of serious, sometimes fatal, cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use and in individuals with pre-existing cardiovascular risk factors. The medicine is contraindicated for use immediately following coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Adverse Events: Serious and potentially fatal gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, can occur without warning symptoms. The risk of these complications is greater with higher doses and in specific populations, notably elderly patients.

Adverse Reactions by Frequency

Adverse reactions are classified by regulatory authorities using international frequency bands, ranging from very common to very rare.

Frequency Classification Examples of Reactions (System-Organ Class)
Very Common (ge 1/10) Dyspepsia, abdominal pain, nausea, vomiting
Common (ge 1/100 to < 1/10) Headache, dizziness, rash, anemia
Uncommon (ge 1/1,000 to < 1/100) Vertigo, elevated liver enzymes, edema
Very Rare (< 1/10,000) Serious skin reactions (e.g., Stevens-Johnson syndrome)

Other Safety Considerations

Official documents also detail the potential for serious hypersensitivity reactions (e.g., anaphylactic reactions), hepatic toxicity, and renal dysfunction. Specific fetal toxicity concerns are noted for use in pregnancy starting at about 20 weeks' gestation and later, which may result in fetal renal issues; the medicine is contraindicated in the third trimester of pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

This section contains the descriptions of overdose and the required emergency actions as explicitly stated in government regulatory sources.

Overdose Scope

Property Official Regulatory Statement
Documented Overdose Presentations Nausea, Vomiting, Epigastric Pain, Drowsiness, and Lethargy are common initial manifestations.
Physiological Systems Affected Gastrointestinal (GI) system (bleeding, perforation), Renal system (Acute Renal Failure), Hepatic system, and Cardiovascular system (Cardiac Arrest, Collapse).
Emergency-Response Statement Immediate medical attention is essential for survival; contact emergency services immediately if the individual is collapsed, seizing, has trouble breathing, or is otherwise unresponsive.
Antidote Status No specific antidote is known for Meloxicam overdose.

Management and Monitoring

  • Supportive Measures: Officially described procedures to reduce systemic exposure include gastric lavage, administration of activated charcoal, and the use of Cholestyramine to accelerate drug elimination.
  • Observation: Due to the documented potential for serious, delayed, or recurring complications, all patients who experience an overdose require medical attention, often necessitating hospital monitoring.

Connection to the Overall Overdose Profile

Regulatory documents define the Melbek overdose profile by detailing a range of documented symptoms, from non-severe complaints to life-threatening systemic organ toxicities, particularly affecting the gastrointestinal, renal, and cardiovascular systems. This profile mandates that immediate medical attention is sought due to the documented risk of severe outcomes and the explicit absence of a specific antidote, requiring that management be focused on officially described supportive and eliminative measures.

Therapeutic Uses of Melbek

What Melbek Treats: Main Uses and Benefits

Melbek is considered relevant for the management of chronic joint disorders and associated symptoms. The medication is primarily used for managing the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA) in adults, and Ankylosing Spondylitis (AS), and is also relevant for Juvenile Idiopathic Arthritis (JIA) in pediatric patients. It is applied across therapeutic domains where additional symptomatic support is needed to address the chronic symptom cluster of persistent joint pain, localized swelling, and stiffness that interferes with daily functioning.

“The medication's role is to support the easing of the overall symptom burden, which contributes to improved day-to-day comfort.”

It is commonly used across conditions presenting with inflammatory or irritative processes, and is applied in addressing moderate-to-severe pain episodes and associated symptoms. This symptomatic assistance helps patients cope more steadily with difficult episodes and assists with maintaining functional stability during symptomatic periods.


Quick Fact: Support for Inflammation and Pain
Primary Therapeutic Focus Managing chronic pain and stiffness associated with inflammatory joint diseases.
Typical Symptom Targets Persistent joint pain, localized swelling, and chronic stiffness.
Pediatric Use Context Symptomatic management of Juvenile Idiopathic Arthritis (JIA).

Eligibility and Restrictions for Use

Who Can and Cannot Use Melbek?

Eligibility for Melbek (Meloxicam) is strictly defined by regulatory documents, outlining populations for whom use is permitted, restricted, or absolutely prohibited.

Contraindicated Populations

Use of Melbek is contraindicated in patients with a known hypersensitivity to meloxicam, aspirin, or any other NSAID. It is also contraindicated in the setting of peri-operative pain for Coronary Artery Bypass Graft (CABG) surgery. Absolute exclusions apply to patients with active or a history of recurrent gastrointestinal bleeding or perforation, as well as those with severe uncontrolled heart failure, severe renal impairment (non-dialyzed), or severe hepatic impairment.

Age and Physiological Restrictions

Population Group Regulatory Status
Pediatric Patients Approved for Juvenile Idiopathic Arthritis (JIA) only in patients ge 2 years of age. Use is not established below this age.
Older Adults (ge 65 years) Eligible, but use with caution and monitoring is required due to increased risk factors.
Pregnancy Contraindicated in the third trimester (from 30 weeks gestation). Avoid use between 20 and 30 weeks gestation.
Lactation Use with caution (Meloxicam is excreted in human milk).

What should I know about interactions with other medicines?

Melbek (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) and may interact with other medications, increasing the risk of adverse effects. It is critical to inform your doctor or pharmacist of all prescription, over-the-counter, and herbal products you use.

Medications to Discuss with Your Healthcare Provider

Drug Class Potential Interaction/Risk Examples of Drugs
Other NSAIDs Increased risk of gastrointestinal bleeding and ulcers. Ibuprofen, naproxen, aspirin (for pain/fever)
Anticoagulants/Antiplatelets Significantly increased risk of serious bleeding. Warfarin, clopidogrel, aspirin (blood-thinning dose)
Corticosteroids Increased risk of gastrointestinal ulcers and bleeding. Prednisone, dexamethasone
Diuretics & Antihypertensives Reduced effectiveness of blood pressure medications and increased risk of kidney problems. Furosemide, ACE inhibitors (e.g., lisinopril), ARBs (e.g., losartan)
Lithium Melbek may increase lithium levels, risking toxicity.
Methotrexate Melbek can increase methotrexate levels, raising the risk of toxicity, especially in high doses.
SSRIs/SNRIs Increased risk of gastrointestinal bleeding. Fluoxetine, venlafaxine
Cyclosporine Increased risk of kidney toxicity.

Co-administration with other NSAIDs is generally not recommended. The combination with medications for high blood pressure or heart failure, blood thinners, lithium, or methotrexate requires close medical monitoring, including kidney function and blood levels of the co-administered drug.

Mechanism of Action

How Melbek Works

Melbek (Meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID) whose mechanism of action centers on modulating the pathway responsible for producing inflammatory mediators. It engages specific enzyme targets to establish its pharmacological activity.


Targeted Enzyme Inhibition

Melbek primarily acts within domains involving enzyme-mediated signaling by inhibiting cyclooxygenase (COX) enzymes, which are critical in the biosynthesis of prostaglandins. This modification of early molecular steps in the arachidonic acid cascade directly limits the production of pro-inflammatory autacoids.


Preferential COX-2 Modulation

The drug exerts a preferential inhibitory effect on COX-2, the enzyme that is typically induced at high levels in affected tissues. This targeted pathway adjustment contributes to alterations in inflammatory mediator levels, which reduces the effects of elevated local concentrations of inflammatory mediators.

Dosage and Administration Information

How to Use Melbek

The administration of Melbek, which contains the active ingredient Meloxicam, follows standardized protocols. The medicine is utilized systemically through both oral (tablet, capsule, suspension) and intravenous (IV) routes.


Standard Dosing and Frequency

Melbek is typically administered once daily for all approved regimens. The standard starting oral dose for adults managing conditions like Osteoarthritis or Rheumatoid Arthritis is 7.5 mg once daily. If needed, the dose may be adjusted to a standard maximum daily dose of 15 mg. The use of Melbek IV solution for acute pain involves a dose of 30 mg, also given once daily.


Administration Context and Adjustments

Oral forms of Melbek may be taken without regard to the timing of meals. When using the oral suspension, the bottle must be gently shaken before measuring the dose.

For intravenous administration, the 30 mg dose is delivered as a bolus injection over a minimum of 15 seconds, and patients must be well hydrated before the injection.

Specific administration rules apply to certain populations. The maximum daily dose is restricted to 7.5 mg for patients undergoing hemodialysis. For pediatric patients (aged two years and older) with Juvenile Idiopathic Arthritis, dosing is calculated by body weight at 0.125 mg/kg once daily, not to exceed the maximum pediatric dose of 7.5 mg per day.

The therapy should be utilized for the shortest duration possible, and the continued need for the medication must be periodically re-evaluated.

Recent Clinical Evidence

Research evidence / Overview of studies for Melbek

Evidence for use in Osteoarthritis (OA) Symptomatic Management

Research exploring how symptoms change over time in Osteoarthritis involved short-term randomized controlled trials (RCTs). These studies typically included adults, often with OA of the knee or hip, and were generally conducted over periods ranging from a few weeks up to several months. The endpoints related to physical discomfort and daily functioning were monitored using standardized assessments.

Studies reported how symptoms evolved in the observed populations, and findings describe patterns observed in these short-term measurements when compared to placebo or other study treatments. Research also examined symptom intensity and variability in these conditions marked by functional limitations.

Evidence for use in Rheumatoid Arthritis (RA) Symptomatic Management

For Rheumatoid Arthritis, Melbek was a focus of studies focusing on episodes where symptoms become more noticeable. Research examined the use of the medicine in adults with active RA, often alongside other treatments. The main endpoints monitored included established measures of disease activity, such as the American College of Rheumatology (ACR) response criteria, as well as joint counts and patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to changes in these markers over the defined study intervals, typically around 12 weeks. Evidence contributes to understanding symptom patterns, particularly endpoints reflecting daily functioning in the observed populations.

Evidence for use in Juvenile Idiopathic Arthritis (JIA) Symptomatic Management

Evidence for the symptomatic management of Juvenile Idiopathic Arthritis (JIA) comes from active-comparator clinical trials involving pediatric patients (ages 2 to 16). These studies focused on outcomes linked to inflammatory states, measured using pediatric-specific response criteria. Research followed the observed populations for up to 12 months, contributing to the broader evidence landscape for this special population.

Duration of Research and Long-term Follow-up Data

The evidence base for Melbek across all indications is structured around short-term or intermediate-term clinical trials that monitored endpoints over weeks or a few months. While some studies, particularly for Ankylosing Spondylitis and JIA, have incorporated follow-up of up to one year, there is limited information for long-term endpoints (beyond 12 months) from the original randomized efficacy trials. Certainty remains low when projecting these findings over the course of multiple years for chronic conditions.

Key Studies & References

  1. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac

Frequently Asked Questions (FAQ)

Common questions about Melbek (FAQ)

Q: Is Melbek the same kind of medicine as Advil or Motrin?

Melbek (meloxicam) and medicines like Advil or Motrin (ibuprofen) are both classified by regulatory authorities as Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Melbek is described as a preferential Cyclooxygenase-2 (COX-2) inhibitor, which targets specific enzymes involved in inflammation. Ibuprofen is typically available over-the-counter and is often used for shorter-term pain relief.


Q: What's the difference between Melbek and other pain relievers?

Melbek is an NSAID, which works by chemically modulating the pathway that produces inflammatory substances in the body. This approach differs from simple pain relievers, such as acetaminophen, which is not an anti-inflammatory drug and works through other mechanisms.

Melbek is also distinct from narcotic pain medicines, which affect the central nervous system and are not anti-inflammatory.


Q: How quickly does Melbek start working after I take it?

According to official product information and pharmacological studies, the concentration of the medicine in the bloodstream typically reaches its maximum level within five to six hours after taking an oral dose.

Because of its pharmacological properties, the medicine is not intended for the relief of sudden, acute pain requiring immediate action.


Q: How long do the effects of Melbek last?

Studies published in regulatory documents indicate that the medicine has a mean elimination half-life that has been observed to vary between 13 and 25 hours. The half-life refers to the time it takes for half of the medicine to be cleared from the body.

This pharmacokinetic profile is consistent with the general once-daily dosing regimen described in regulatory documents.


Q: Is Melbek a narcotic or addictive pain medicine?

Official documents classify Melbek as a Nonsteroidal Anti-inflammatory Drug (NSAID).

It is not classified as a narcotic or opioid pain medicine by regulatory authorities.


Q: Are there any common foods or drinks to avoid while taking Melbek?

Official safety warnings state that consuming alcohol while taking this medicine significantly increases the risk of serious gastrointestinal bleeding and ulceration.

Additionally, regulatory information suggests discussing the use of certain foods, such as grapefruit, and tobacco with a healthcare provider, as they may increase drug exposure or health risks.


Q: Is it normal to feel tired or dizzy after starting Melbek?

Official safety information lists dizziness as a common side effect of Melbek. While 'tiredness' or 'fatigue' is not always listed as a common reaction in the tables, the side effect profile includes central nervous system effects that can impact alertness.

If any changes in alertness are experienced, consulting a healthcare professional is consistent with patient safety information.


Q: Does Melbek interact with common supplements like fish oil or multivitamins?

Official safety information advises caution with certain supplements, particularly those that may affect blood clotting, such as Ginkgo biloba, Ginger, Garlic, Ginseng, and Turmeric.

The use of these supplements alongside Melbek may increase the risk of bleeding. Official patient safety information advises informing a doctor or pharmacist about all supplements being used.


Q: Is it okay to drive or operate machinery while taking Melbek?

Official safety information warns that Melbek can cause side effects such as dizziness, blurred vision, and drowsiness.

Official patient information states that individuals experiencing these effects should exercise caution and avoid driving or operating heavy machinery.


Q: Can I take Melbek along with Tylenol (acetaminophen)?

The official drug labeling does not indicate a specific adverse drug-drug interaction between Melbek (an NSAID) and acetaminophen (Tylenol).

However, it is important to review the recommended limits for any medicine being used. Reviewing co-administration with a healthcare provider is recommended to ensure safe use.


Q: Does taking Melbek require any special monitoring or blood tests?

Close medical monitoring, which may include kidney function tests and checking blood levels, is required when Melbek is taken with certain other prescription drugs, such as blood thinners or high-dose methotrexate.

Monitoring may also be necessary for patients with certain pre-existing health conditions.


Q: Does Melbek affect fertility or hormone levels?

Official documents state that based on its mechanism of action, Melbek may interfere with the natural rupture of ovarian follicles in women. This has been linked to reversible difficulties in conceiving.

If a woman is having difficulties becoming pregnant, official documents state that withdrawal of the medicine may be necessary.


Q: What is the difference between Melbek and a steroid?

Melbek is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) which works by targeting the COX enzyme pathway to limit inflammatory chemicals.

In contrast, steroids (corticosteroids) belong to a separate class of medicines and work by broadly suppressing the immune and inflammatory response, which is a different mechanism.


Q: How is Melbek eliminated from the body?

Pharmacokinetic studies show that Melbek is extensively metabolized into inactive forms within the body. These inactive substances are then eliminated.

The excretion of the medicine occurs in similar amounts through both the urine and in the feces.


Q: If I take other prescription medications, how do I check for interactions with Melbek?

Regulatory patient counseling information emphasizes the importance of informing your doctor or pharmacist about every product you use, including all prescriptions, over-the-counter medicines, and herbal supplements.

This review allows the healthcare professional to perform a drug interaction check and confirm the suitability of use.


Q: Can I drink alcohol while using Melbek?

Official safety warnings indicate that drinking alcohol while taking Melbek is advised against.

This combination poses a significantly increased risk of serious gastrointestinal adverse events, including bleeding and ulcers.

How should Melbek be stored and disposed of?

How to Store and Dispose of Melbek (Meloxicam)

Melbek must be stored according to official regulatory requirements to ensure product integrity and safety.

Official Storage Conditions

Meloxicam tablets require storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The medicine must be protected from light and kept in its original container.

Specific liquid formulations, such as oral suspension, must not be frozen or refrigerated and may have a limited stability period (e.g., 30 days) after the container is opened. It is a mandatory requirement to store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Melbek must be disposed of in accordance with official FDA and local environmental guidelines. The medication must not be flushed down the toilet, poured down a drain, or thrown into wastewater, unless a regulatory program specifically instructs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Melbek found in:

A-Z Index: